Oncolys BioPharma has agreed to purchase an additional 8.4% stake in Precision Virologics from US-based oncolytic virus immunotherapy products developer Unleash Immuno Oncolytics.

As part of the acquisition, Oncolys BioPharma will purchase 294,118 shares of Precision Virologics from Unleash for $0.33m. Oncolys BioPharma’s stake will then increase from the existing 14.6% to 23%.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
“Alira Health has announced the acquisition of Clinical Assistance Programs (CAP).”

Oncolys BioPharma is a biopharmaceutical company based in Japan, while Precision Virologics is a biotechnology company based in the US.

Unleash Immuno Oncolytics has simultaneously announced plans to raise $3m through the private placement of convertible bonds.

Alira Health has announced the acquisition of Clinical Assistance Programs (CAP).

Based in the US, Alira Health is an international healthcare and life science advisory firm, while CAP is involved in providing clinical trial management and consulting services.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NL-HOLDING has acquired ProCrea Group, Archimed and Instituto de Medicina Reproductiva (IMER).

The German healthcare services provider has acquired all three companies in partnership with Oaktree Capital Management.

ProCrea and Instituto de Medicina Reproductiva are assisted-reproduction service providers based in Switzerland and Spain respectively, while Archimedis is an Italian company involved in the provision of specialised diagnostic services.